# First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

> **NCT05828459** · PHASE1 · RECRUITING · sponsor: **Onward Therapeutics** · enrollment: 150 (estimated)

## Conditions studied

- Hematological Malignancy
- Solid Tumor

## Interventions

- **DRUG:** OT-A201
- **DRUG:** IMids
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** TBD Compound

## Key facts

- **NCT ID:** NCT05828459
- **Lead sponsor:** Onward Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-10
- **Primary completion:** 2027-01
- **Final completion:** 2027-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05828459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05828459, "First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05828459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*